{"id":76880,"date":"2026-01-29T12:03:53","date_gmt":"2026-01-29T12:03:53","guid":{"rendered":"https:\/\/english.saigonbiz.com\/vn\/skye-bioscience-highlights-attributes-of-its-peripherally-restricted-cb1-inhibitor-antibody-at-keystone-obesity-conference\/"},"modified":"2026-01-29T12:03:53","modified_gmt":"2026-01-29T12:03:53","slug":"skye-bioscience-highlights-attributes-of-its-peripherally-restricted-cb1-inhibitor-antibody-at-keystone-obesity-conference","status":"publish","type":"post","link":"https:\/\/english.saigonbiz.com\/vn\/skye-bioscience-highlights-attributes-of-its-peripherally-restricted-cb1-inhibitor-antibody-at-keystone-obesity-conference\/","title":{"rendered":"Skye Bioscience Highlights Attributes of its Peripherally-restricted CB1 Inhibitor Antibody at Keystone Obesity Conference"},"content":{"rendered":"<div>\n<p align=\"justify\">SAN DIEGO, Jan.  29, 2026  (GLOBE NEWSWIRE) &#8212; Skye Bioscience, Inc. (Nasdaq: SKYE) (\u201cSkye\u201d) a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, today presented a poster titled &#8220;Investigating the Efficacy of Nimacimab Alone or in Combination with Tirzepatide, and as a Maintenance Therapy Post Tirzepatide Discontinuation in a Diet-Induced Obesity (DIO) Mouse Model&#8221; at Keystone\u2019s conference, Obesity Therapeutics: Unlocking Benefits and Minimizing Side Effects.<\/p>\n<p>Skye\u2019s presentation addressed the following questions regarding the ability of its peripherally-restricted CB1-inhibitor antibody:<\/p>\n<ul type=\"disc\">\n<li style=\"margin-top:6pt;\">Can nimacimab enhance optimal and suboptimal doses of incretin agonists?<\/li>\n<li style=\"margin-top:6pt;\">How durable is nimacimab\u2019s effect on weight loss after treatment discontinuation?<\/li>\n<li style=\"margin-top:6pt;\">Can nimacimab be used as a maintenance therapy after tirzepatide discontinuation?<\/li>\n<li style=\"margin-top:6pt;\">Is caloric-restriction the primary mechanism of nimacimab-driven weight loss?\n<\/li>\n<\/ul>\n<p>Key takeaways from the DIO studies:<\/p>\n<ul type=\"disc\">\n<li style=\"margin-top:6pt;\">Nimacimab showed significant additive weight loss effects when combined with suboptimal or clinically active dose levels of tirzepatide (39% and 46% weight loss respectively).<\/li>\n<li style=\"margin-top:6pt;\">Nimacimab weight loss was durable after treatment discontinuation.<\/li>\n<li style=\"margin-top:6pt;\">Nimacimab treatment after tirzepatide discontinuation improved the weight rebound profile (regain blunted by ~80%).<\/li>\n<li style=\"margin-top:6pt;\">Nimacimab weight loss was not primarily driven by caloric restriction.<\/li>\n<li style=\"margin-top:6pt;\">Nimacimab enhanced weight loss induced by semaglutide.\n<\/li>\n<\/ul>\n<p align=\"justify\">Chris Twitty, PhD, Chief Scientific Officer of Skye, who presented the poster, commented: \u201cThese findings suggest that nimacimab, when combined with lower and more tolerable incretin agonist doses, may achieve a favorable safety profile while still driving meaningful efficacy. This approach may help support longer treatment adherence and provide a more sustainable option for long-term weight management.\u201d<\/p>\n<p>Click here to see the <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=aXUeLPSslb4G-Lt14-AICO9NL9txcg6zPSx7ar_DmpHdnv2Dp46jZcPiCc9no516W9Gt2xEjPDeYbtTsBsZLC46E9Z8iwmbxMiHhEXe_SOOMRQGRrND6LPIrgtN20A_o\" rel=\"nofollow\" target=\"_blank\" title=\"\"><u>poster<\/u><\/a>.<\/p>\n<p><strong>About Nimacimab<\/strong><\/p>\n<p align=\"justify\">Nimacimab is a potential first-in-class, peripherally-restricted monoclonal antibody inhibitor of the CB1 receptor. Unlike previous CB1-targeting drugs, nimacimab is designed to avoid central nervous system penetration, potentially limiting neuropsychiatric side effects seen with small-molecule antagonists. As a non-incretin, non-peptide agent, nimacimab acts independently of the GLP-1 pathway and has also demonstrated additive or complementary effects in combination with incretin-based therapies in preclinical and clinical studies.<\/p>\n<p><strong>Skye Bioscience <\/strong><\/p>\n<p align=\"justify\">Skye is focused on unlocking new therapeutic pathways for metabolic health through the development of next-generation molecules that modulate G-protein coupled receptors. Skye&#8217;s strategy leverages biologic targets with substantial human proof of mechanism for the development of first-in-class therapeutics with clinical and commercial differentiation. Skye is conducting a Phase 2a clinical trial (<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=lS6GBrJp3ex58SWFAVD3I9ewDVd2zZ8R1R1w_Yp9K_Z2YLiPbVlmRF-YwAzTBOwdn5Bs_ULqju9-ZaunPnQUd8Avrq44_lmMxml-ghQ_iRMEm9yoo_n2lL4gR2i9ZafASxPHefHHChDJSFumAfYrXw==\" rel=\"nofollow\" target=\"_blank\" title=\"\"><u>ClinicalTrials.gov: NCT06577090<\/u><\/a>) in obesity for nimacimab, a negative allosteric modulating antibody that peripherally inhibits CB1. This study is also assessing the combination of nimacimab and a GLP-1R agonist (Wegovy\u00ae). For more information, please visit: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=giLjo8bRr12WWfQltmM84zdKlgA7wSd6co2fMCwHX6hdooSsZCMQlJ0tXQybWqmjf6VGxAHI5n6o1kOJRUHDgIWumXp6sJVR8Y3vVdtYbYM=\" rel=\"nofollow\" target=\"_blank\" title=\"\"><u>www.skyebioscience.com<\/u><\/a>. Connect with us on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=u6ANa2KVGCdaPK72_a19-WsE0Rgq5kYjHnvlUAXpDytOe63w-OSmVpCp4PevUfmRhedNaFZ6lCeEfHGdpC9GLw==\" rel=\"nofollow\" target=\"_blank\" title=\"\"><u>X<\/u><\/a> and <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=NeF123An2FZTLPPAQvWebEZ_8HJhB7SbZR-3tRx2pZeiAaf708jen-qA18ufV9s1Skj0vi_IAlHq8h74AUzNdBpUPv39cxbFs1GCyM6gA8Y=\" rel=\"nofollow\" target=\"_blank\" title=\"\"><u>LinkedIn<\/u><\/a>.<\/p>\n<p><strong>CONTACTS<\/strong><\/p>\n<p><strong>Investor Relations<br \/><\/strong>ir@skyebioscience.com<br \/>(858) 410-0266<br \/>LifeSci Advisors, Mike Moyer<br \/>mmoyer@lifesciadvisors.com<br \/>(617) 308-4306<\/p>\n<p><strong>Media Inquiries<br \/><\/strong>LifeSci Communications, Michael Fitzhugh<br \/>mfitzhugh@lifescicomms.com<br \/>(628) 234-3889<\/p>\n<p><strong>FORWARD-LOOKING STATEMENTS<\/strong><\/p>\n<p align=\"justify\">This press release includes \u201cforward-looking statements\u201d within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release other than statements of historical fact should be considered forward-looking statements, including, without limitation, statements relating to: Skye&#8217;s future plans and prospects, any expectations regarding the efficacy and therapeutic potential of nimacimab, including based on DIO models. When used herein, words including \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccan,\u201d \u201ccontinue,\u201d \u201ccould,\u201d \u201cdesigned,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cforecast,\u201d \u201cgoal,\u201d \u201cintend,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201cplan,\u201d \u201cplanning,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cshould,\u201d \u201ctarget,\u201d \u201cwill,\u201d \u201cwould\u201d and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements use these words or expressions. All forward-looking statements are based upon the Company\u2019s current expectations and various assumptions. The Company believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. The Company may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important risks and uncertainties, including, without limitation, the initiation and design of any future clinical trials will be impacted by the Company\u2019s capital resources, the Company\u2019s ability to obtain additional sources of capital needed to run an additional Phase 2 clinical trial, program considerations and potentially other factors outside the Company\u2019s control; the Company\u2019s dependence on third parties in connection with product manufacturing; research and preclinical and clinical testing; the Company\u2019s ability to advance, obtain regulatory approval of and ultimately commercialize nimacimab, competitive products or approaches limiting the commercial value of nimacimab; the timing and results of preclinical and clinical trials; the Company\u2019s ability to fund development activities and achieve development goals; the impact of any global pandemics, inflation, supply chain issues, government shutdowns, high interest rates, adverse regulatory changes; the Company\u2019s ability to protect its intellectual property; risks associated with the Company\u2019s common stock and the other important factors discussed under the caption \u201cRisk Factors\u201d in the Company\u2019s filings with the Securities and Exchange Commission, including in its Annual Report on Form 10-K for the year ended December 31, 2024, which are accessible on the SEC\u2019s website at www.sec.gov and the Investors section of the Company\u2019s website. Any such forward-looking statements represent management\u2019s estimates as of the date of this press release. While the Company may elect to update such forward-looking statements at some point in the future, except as required by law, it disclaims any obligation to do so, even if subsequent events cause the Company\u2019s views to change. These forward-looking statements should not be relied upon as representing the Company\u2019s views as of any date subsequent to the date of this press release.<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/ZWE1MDY3YWUtZTc1Yy00MDcxLWJkNmEtODQzYjM3OWZkZjAyLTUwMDEyMDM5Ny0yMDI2LTAxLTI5LWVu\/tiny\/Skye-Bioscience-Inc-.png\" referrerpolicy=\"no-referrer-when-downgrade\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SAN DIEGO, Jan. 29, 2026 (GLOBE NEWSWIRE) &#8212; Skye Bioscience, Inc. (Nasdaq: SKYE) (\u201cSkye\u201d) a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, today presented a poster titled &#8220;Investigating the Efficacy of Nimacimab Alone or in Combination with Tirzepatide, and as a Maintenance Therapy Post Tirzepatide Discontinuation [&#8230;]\n","protected":false},"author":1,"featured_media":76881,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-76880","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-pr-newswire"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v21.6 (Yoast SEO v21.6) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Skye Bioscience Highlights Attributes of its Peripherally-restricted CB1 Inhibitor Antibody at Keystone Obesity Conference - Biz and Live in Saigon<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/english.saigonbiz.com\/vn\/skye-bioscience-highlights-attributes-of-its-peripherally-restricted-cb1-inhibitor-antibody-at-keystone-obesity-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Skye Bioscience Highlights Attributes of its Peripherally-restricted CB1 Inhibitor Antibody at Keystone Obesity Conference\" \/>\n<meta property=\"og:description\" content=\"SAN DIEGO, Jan. 29, 2026 (GLOBE NEWSWIRE) &#8212; Skye Bioscience, Inc. (Nasdaq: SKYE) (\u201cSkye\u201d) a clinical-stage biotechnology company focused on\" \/>\n<meta property=\"og:url\" content=\"https:\/\/english.saigonbiz.com\/vn\/skye-bioscience-highlights-attributes-of-its-peripherally-restricted-cb1-inhibitor-antibody-at-keystone-obesity-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Biz and Live in Saigon\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/SaigonbizGroup\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-29T12:03:53+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/01\/Skye-Bioscience-Inc-1-1.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1\" \/>\n\t<meta property=\"og:image:height\" content=\"1\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/skye-bioscience-highlights-attributes-of-its-peripherally-restricted-cb1-inhibitor-antibody-at-keystone-obesity-conference\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/skye-bioscience-highlights-attributes-of-its-peripherally-restricted-cb1-inhibitor-antibody-at-keystone-obesity-conference\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\"},\"headline\":\"Skye Bioscience Highlights Attributes of its Peripherally-restricted CB1 Inhibitor Antibody at Keystone Obesity Conference\",\"datePublished\":\"2026-01-29T12:03:53+00:00\",\"dateModified\":\"2026-01-29T12:03:53+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/skye-bioscience-highlights-attributes-of-its-peripherally-restricted-cb1-inhibitor-antibody-at-keystone-obesity-conference\/\"},\"wordCount\":930,\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"articleSection\":[\"Pr Newswire\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/skye-bioscience-highlights-attributes-of-its-peripherally-restricted-cb1-inhibitor-antibody-at-keystone-obesity-conference\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/skye-bioscience-highlights-attributes-of-its-peripherally-restricted-cb1-inhibitor-antibody-at-keystone-obesity-conference\/\",\"name\":\"Skye Bioscience Highlights Attributes of its Peripherally-restricted CB1 Inhibitor Antibody at Keystone Obesity Conference - Biz and Live in Saigon\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\"},\"datePublished\":\"2026-01-29T12:03:53+00:00\",\"dateModified\":\"2026-01-29T12:03:53+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/skye-bioscience-highlights-attributes-of-its-peripherally-restricted-cb1-inhibitor-antibody-at-keystone-obesity-conference\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/english.saigonbiz.com\/vn\/skye-bioscience-highlights-attributes-of-its-peripherally-restricted-cb1-inhibitor-antibody-at-keystone-obesity-conference\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/skye-bioscience-highlights-attributes-of-its-peripherally-restricted-cb1-inhibitor-antibody-at-keystone-obesity-conference\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/english.saigonbiz.com\/vn\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Skye Bioscience Highlights Attributes of its Peripherally-restricted CB1 Inhibitor Antibody at Keystone Obesity Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"name\":\"Biz and Live in Saigon\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\",\"name\":\"SaigonBiz Media\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"width\":512,\"height\":512,\"caption\":\"SaigonBiz Media\"},\"image\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/SaigonbizGroup\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"caption\":\"admin\"},\"sameAs\":[\"https:\/\/english.saigonbiz.com\/vn\"],\"url\":\"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Skye Bioscience Highlights Attributes of its Peripherally-restricted CB1 Inhibitor Antibody at Keystone Obesity Conference - Biz and Live in Saigon","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/english.saigonbiz.com\/vn\/skye-bioscience-highlights-attributes-of-its-peripherally-restricted-cb1-inhibitor-antibody-at-keystone-obesity-conference\/","og_locale":"en_US","og_type":"article","og_title":"Skye Bioscience Highlights Attributes of its Peripherally-restricted CB1 Inhibitor Antibody at Keystone Obesity Conference","og_description":"SAN DIEGO, Jan. 29, 2026 (GLOBE NEWSWIRE) &#8212; Skye Bioscience, Inc. (Nasdaq: SKYE) (\u201cSkye\u201d) a clinical-stage biotechnology company focused on","og_url":"https:\/\/english.saigonbiz.com\/vn\/skye-bioscience-highlights-attributes-of-its-peripherally-restricted-cb1-inhibitor-antibody-at-keystone-obesity-conference\/","og_site_name":"Biz and Live in Saigon","article_publisher":"https:\/\/www.facebook.com\/SaigonbizGroup","article_published_time":"2026-01-29T12:03:53+00:00","og_image":[{"width":1,"height":1,"url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/01\/Skye-Bioscience-Inc-1-1.png","type":"image\/png"}],"author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/english.saigonbiz.com\/vn\/skye-bioscience-highlights-attributes-of-its-peripherally-restricted-cb1-inhibitor-antibody-at-keystone-obesity-conference\/#article","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/skye-bioscience-highlights-attributes-of-its-peripherally-restricted-cb1-inhibitor-antibody-at-keystone-obesity-conference\/"},"author":{"name":"admin","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6"},"headline":"Skye Bioscience Highlights Attributes of its Peripherally-restricted CB1 Inhibitor Antibody at Keystone Obesity Conference","datePublished":"2026-01-29T12:03:53+00:00","dateModified":"2026-01-29T12:03:53+00:00","mainEntityOfPage":{"@id":"https:\/\/english.saigonbiz.com\/vn\/skye-bioscience-highlights-attributes-of-its-peripherally-restricted-cb1-inhibitor-antibody-at-keystone-obesity-conference\/"},"wordCount":930,"publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"articleSection":["Pr Newswire"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/english.saigonbiz.com\/vn\/skye-bioscience-highlights-attributes-of-its-peripherally-restricted-cb1-inhibitor-antibody-at-keystone-obesity-conference\/","url":"https:\/\/english.saigonbiz.com\/vn\/skye-bioscience-highlights-attributes-of-its-peripherally-restricted-cb1-inhibitor-antibody-at-keystone-obesity-conference\/","name":"Skye Bioscience Highlights Attributes of its Peripherally-restricted CB1 Inhibitor Antibody at Keystone Obesity Conference - Biz and Live in Saigon","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#website"},"datePublished":"2026-01-29T12:03:53+00:00","dateModified":"2026-01-29T12:03:53+00:00","breadcrumb":{"@id":"https:\/\/english.saigonbiz.com\/vn\/skye-bioscience-highlights-attributes-of-its-peripherally-restricted-cb1-inhibitor-antibody-at-keystone-obesity-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/english.saigonbiz.com\/vn\/skye-bioscience-highlights-attributes-of-its-peripherally-restricted-cb1-inhibitor-antibody-at-keystone-obesity-conference\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/english.saigonbiz.com\/vn\/skye-bioscience-highlights-attributes-of-its-peripherally-restricted-cb1-inhibitor-antibody-at-keystone-obesity-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/english.saigonbiz.com\/vn\/"},{"@type":"ListItem","position":2,"name":"Skye Bioscience Highlights Attributes of its Peripherally-restricted CB1 Inhibitor Antibody at Keystone Obesity Conference"}]},{"@type":"WebSite","@id":"https:\/\/english.saigonbiz.com\/vn\/#website","url":"https:\/\/english.saigonbiz.com\/vn\/","name":"Biz and Live in Saigon","description":"","publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/english.saigonbiz.com\/vn\/#organization","name":"SaigonBiz Media","url":"https:\/\/english.saigonbiz.com\/vn\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","width":512,"height":512,"caption":"SaigonBiz Media"},"image":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/SaigonbizGroup"]},{"@type":"Person","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","caption":"admin"},"sameAs":["https:\/\/english.saigonbiz.com\/vn"],"url":"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/76880","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/comments?post=76880"}],"version-history":[{"count":0,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/76880\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media\/76881"}],"wp:attachment":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media?parent=76880"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/categories?post=76880"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/tags?post=76880"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}